Taylan Gurgenci

May 1, 2024

Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial

Abstract Background: Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There…

October 14, 2023

Exploring potential anti-inflammatory effects of medicinal cannabis

Abstract Purpose: Inflammation is thought to play a key role in malignant disease and may play a significant part in…

November 6, 2022

‘What price do you put on your health?’: Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer

Abstract Introduction: Following 2016 legislation permitting limited access to cannabis for research and medicinal purposes, the number of randomized clinical…